A Modular, Multi-arm, Multi-part, First Time in Patient Study to Evaluate the Safety and Tolerability of OMO-1, Alone and in Combination With Anti-cancer Treatments, in Patients With Locally Advanced, Unresectable or Metastatic Solid Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs JNJ 38877618 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Octimet Oncology
- 24 Aug 2017 Status changed from not yet recruiting to recruiting.
- 10 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Aug 2017.
- 05 May 2017 New trial record